Prestige Consumer Healthcare Inc. PBH
Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to "we," "us," "our," the "Company" or "Prestige" refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., "2026") refers to our fiscal year ended March 31 of that year.
We formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter ("OTC") health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage. Our ultimate success is dependent on several factors, including our ability to:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.09B | $1.14B | $1.13B | $1.13B | $1.09B | $943.4M | $963.0M | $975.8M | $1.04B | $882.1M |
| Cost of revenue | $493.1M | $503.3M | $500.9M | $502.4M | $466.2M | $395.9M | $410.8M | $420.2M | $464.7M | $381.8M |
| Gross profit | $595.6M | $634.5M | $624.4M | $625.3M | $620.6M | $547.5M | $552.2M | $555.6M | $576.5M | $500.3M |
| SG&A | $116.4M | $108.2M | $106.2M | $107.4M | $107.5M | $83.1M | $89.1M | $89.8M | $85.4M | $89.1M |
| Total operating expenses | $286.2M | $297.7M | $282.0M | $647.7M | $290.7M | $250.1M | $261.1M | $488.1M | $361.0M | $294.6M |
| Operating income | $309.4M | $336.8M | $342.4M | -$22.4M | $329.9M | $297.4M | $291.2M | $67.5M | $215.5M | $205.6M |
| Interest expense | $42.3M | $47.6M | $67.2M | $69.2M | $64.3M | — | — | — | — | — |
| Pre-tax income | $257.5M | $284.2M | $276.0M | -$93.9M | $262.5M | $204.1M | $191.2M | -$38.1M | $107.1M | $110.8M |
| Income tax | $67.2M | $69.6M | $66.7M | $11.6M | $57.1M | $39.4M | $48.9M | $2.3M | $232.5M | $41.5M |
| Net income | $190.3M | $214.6M | $209.3M | -$82.3M | $205.4M | $164.7M | $142.3M | -$35.8M | $339.6M | $69.4M |
| EPS, basic | 3.93 | 4.32 | 4.21 | -1.65 | 4.09 | 3.28 | 2.81 | -0.69 | 6.40 | 1.31 |
| EPS, diluted | 3.91 | 4.29 | 4.17 | -1.65 | 4.04 | 3.25 | 2.78 | -0.69 | 6.34 | 1.30 |
| Shares, diluted (wtd. avg.) | $48.7M | $50.1M | $50.2M | $49.9M | $50.8M | $50.6M | $51.1M | $52.1M | $53.5M | $53.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $63.9M | $97.9M | $46.5M | $58.5M | $27.2M | $32.3M | $94.8M | $27.5M | $32.5M | $41.9M |
| Receivables | $191.9M | $194.3M | $176.8M | $167.0M | $139.3M | $114.7M | $150.5M | $148.8M | $140.9M | $136.7M |
| Inventory | $159.1M | $147.7M | $138.7M | $162.1M | $120.3M | $115.0M | $116.0M | $119.9M | $118.5M | $115.6M |
| Total current assets | $431.5M | $448.3M | $375.0M | $391.7M | $293.3M | $269.8M | $365.7M | $300.9M | $303.5M | $334.4M |
| Property, plant and equipment | $121.7M | $74.5M | $76.5M | $70.4M | $71.3M | $70.1M | $56.0M | $51.2M | $52.6M | $50.6M |
| Goodwill | $581.1M | $527.4M | $527.7M | $527.6M | $579.0M | $578.1M | $575.2M | $578.6M | $620.1M | $615.3M |
| Other intangibles | $2.30B | $2.30B | $2.32B | $2.34B | $2.70B | $2.48B | $2.48B | $2.51B | $2.78B | $2.90B |
| Total assets | $3.49B | $3.40B | $3.32B | $3.35B | $3.67B | $3.43B | $3.51B | $3.44B | $3.76B | $3.91B |
| Accounts payable | $22.8M | $18.9M | $39.0M | $62.7M | $55.8M | $46.0M | $62.4M | $56.6M | $61.4M | $70.2M |
| Total current liabilities | $120.9M | $106.6M | $117.0M | $160.7M | $143.4M | $122.1M | $149.9M | $127.0M | $123.2M | $162.0M |
| Long-term debt | $994.0M | $992.4M | $1.13B | $1.35B | $1.48B | $1.48B | $1.73B | $1.80B | $1.99B | $2.19B |
| Total liabilities | $1.61B | $1.57B | $1.66B | $1.91B | $2.09B | $2.07B | $2.34B | $2.35B | $2.58B | $3.09B |
| Retained earnings | $1.75B | $1.56B | $1.34B | $1.13B | $1.21B | $1.01B | $844.1M | $701.8M | $736.3M | $396.7M |
| Total equity | $1.89B | $1.83B | $1.66B | $1.45B | $1.58B | $1.36B | $1.17B | $1.10B | $1.18B | $822.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $257.6M | $251.5M | $248.9M | $229.7M | $259.9M | $235.6M | $217.1M | $189.3M | $210.1M | $148.7M |
| Depreciation and amortisation | $31.3M | $30.2M | $30.7M | $32.6M | $32.1M | $30.2M | $29.0M | $31.8M | $33.4M | $25.8M |
| Stock-based compensation | $10.8M | $11.2M | $14.0M | $12.4M | — | — | — | — | — | $8.1M |
| Capital expenditure | $11.2M | $8.2M | $9.6M | $7.8M | $9.6M | $22.2M | $14.6M | $10.5M | $12.5M | $3.0M |
| Investing cash flow | -$136.8M | -$17.5M | -$20.1M | -$11.6M | -$256.5M | -$22.2M | -$16.6M | $55.4M | -$11.6M | -$694.6M |
| Financing cash flow | -$156.1M | -$182.1M | -$241.0M | -$185.8M | -$7.6M | -$279.4M | -$131.4M | -$249.3M | -$209.0M | $561.0M |
| Buybacks | $156.3M | $51.5M | $25.0M | $50.0M | $0 | $11.9M | $56.7M | $50.0M | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001295947-26-000021.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |